돼지 인플루엔자 백신 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global swine flu vaccines market size is expected to reach USD 40.58 Billion in 2034 from USD 19.82 Billion in 2025, growing at a CAGR of 8.29 during 2026-2034.This market has grown steadily due to increasing efforts to prevent and control influenza outbreaks among human and animal populations. Swine flu vaccines play a crucial role in reducing disease transmission, minimizing healthcare burdens, and protecting public health. Rising awareness regarding pandemic preparedness and vaccination programs has supported market growth. Government health initiatives and ongoing surveillance efforts have further strengthened demand for effective influenza prevention solutions.

Several factors drive market expansion, including recurring influenza outbreaks, increasing investments in vaccine development, and advancements in biotechnology. Healthcare authorities and livestock industries are prioritizing vaccination programs to minimize economic losses and disease-related complications. Continuous research efforts aimed at improving vaccine efficacy and production capabilities have enhanced market opportunities. Furthermore, global collaboration among healthcare organizations has contributed to broader vaccine availability and adoption.

Future growth prospects remain strong as governments continue emphasizing infectious disease prevention and pandemic preparedness strategies. Technological innovations in vaccine development, including advanced manufacturing platforms and improved formulations, are expected to support market advancement. Expanding healthcare access in developing regions and growing public awareness regarding immunization benefits will further drive demand. As disease surveillance systems become more sophisticated, the market is likely to experience continued growth.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Vaccine Type

• Intranasal
• Toxoid
• Conjugate
• Inactivated Vaccine
• Attenuated Vaccine

By Treatment Type

• Influenza
• Meningococcal
• Cervical Cancer
• Pneumococcal
• Hepatitis
• Measles
• Mumps
• Rubella

By End User

• Hospital
• Clinic
• Other End User

COMPANIES PROFILED

• Pfizer Inc., Roche Holding AG, Merck & Co. Inc., Sanofi S.A., AstraZeneca Plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Mylan N.V., Moderna Inc., Baxter International Inc., Zoetis Inc.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL SWINE FLU VACCINES MARKET: BY VACCINE TYPE 2022-2034 (USD MN and Million Doses)

• 4.1. Market Analysis, Insights and Forecast Vaccine Type
• 4.2. Intranasal Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.3. Toxoid Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.4. Conjugate Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.5. Inactivated Vaccine Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.6. Attenuated Vaccine Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL SWINE FLU VACCINES MARKET: BY TREATMENT TYPE 2022-2034 (USD MN and Million Doses)

• 5.1. Market Analysis, Insights and Forecast Treatment Type
• 5.2. Influenza Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.3. Meningococcal Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.4. Cervical Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.5. Pneumococcal Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.6. Hepatitis Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.7. Measles Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.8. Mumps Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.9. Rubella Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL SWINE FLU VACCINES MARKET: BY END USER 2022-2034 (USD MN and Million Doses)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Hospital Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.3. Clinic Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.4. Other End User Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 7. GLOBAL SWINE FLU VACCINES MARKET: BY REGION 2022-2034 (USD MN and Million Doses)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.2.1 By Vaccine Type
  • 7.2.2 By Treatment Type
  • 7.2.3 By End User
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.3.1 By Vaccine Type
  • 7.3.2 By Treatment Type
  • 7.3.3 By End User
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.4.1 By Vaccine Type
  • 7.4.2 By Treatment Type
  • 7.4.3 By End User
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.5.1 By Vaccine Type
  • 7.5.2 By Treatment Type
  • 7.5.3 By End User
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.6.1 By Vaccine Type
  • 7.6.2 By Treatment Type
  • 7.6.3 By End User
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL SWINE FLU VACCINES INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Pfizer Inc
  • 9.2.2 Roche Holding AG
  • 9.2.3 Merck & Co. Inc
  • 9.2.4 Sanofi S.A
  • 9.2.5 AstraZeneca Plc
  • 9.2.6 Abbott Laboratories
  • 9.2.7 Novartis AG
  • 9.2.8 GlaxoSmithKline Plc
  • 9.2.9 Boehringer Ingelheim International GmbH
  • 9.2.10 Mylan N.V
  • 9.2.11 Moderna Inc
  • 9.2.12 Baxter International Inc
  • 9.2.13 Zoetis Inc